Nivolumab not recommend for relapsed or metastatic head-and-neck cancer on the NHS - The Institute of Cancer Research

The Institute of Cancer Research

Nivolumab not recommend for relapsed or metastatic head-and-neck cancer on the NHS The Institute of Cancer Research Commenting on the draft decision, Professor Harrington said: “It is disappointing and frustrating that today's decision means doctors will not be able to offer this game-changing immunotherapy to patients with advanced head-and-neck cancer. Once it has ...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oZePHK
via IFTTT